October 31, 2016
Finnish patent office accepts Faron’s new formulation for a respiratory orphan disease ARDS
Finish patent office has accepts Faron’s new formulation for a respiratory orphan disease ARDS
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Markku Jalkanen
October 24, 2016
Faron recruits patients for the Japanese Traumakine Phase III trial
Faron Pharmaceuticals (Faron), the clinical stage biopharmaceutical company, has recruited the first patient in the Japanese Phase III pivotal clinical trial for the…
July 25, 2016
Faron and Abzena in cancer medicine Clevegen manufacture deal
Faron and Abzena in cancer medicine Clevegen manufacture deal
November 30, 2015
Faron: Clevegen can be used as immunotherapy product
A publication on Clever-1 function related to Faron Pharmaceuticals’ novel cancer immunotherapy antibody Clevegen, was published in journal of the American Association of Immunology.
November 17, 2015
Faron Pharmaceuticals Oy joins London stock exchange
Faron Pharmaceuticals Oy (Faron), the clinical stage biopharmaceutical company, has started dealing its Ordinary Shares on the AIM market of the London Stock Exchange with effect from 8.00 a.m. Tuesday after placing and subscription for 3,846,154 new Ordinary Shares, raising £10.0 million at a price of 260p per ordinary.
November 3, 2015
Faron Pharmaceuticals secures Clevegen production with Swiss Selexis
Finland’s Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company, has entered into an agreement with Swiss-based Selexis SA for producing Novel Cancer Immunotherapy Clevegen.